Ultragenyx Pharmaceutical Inc. (RARE)

Market Cap	3.81B
Revenue (ttm)	522.75M
Net Income (ttm)	-558.99M
Shares Out	92.28M
EPS (ttm)	-6.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,081,371
Open	40.47
Previous Close	40.00
Day's Range	40.19 - 41.33
52-Week Range	37.02 - 60.37
Beta	0.58
Analysts	Strong Buy
Price Target	92.00 (+122.87%)
Earnings Date	Feb 13, 2025

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and ad...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2014
• Employees: 1,276
• Stock Exchange: NASDAQ
• Ticker Symbol: RARE
• Website: https://www.ultragenyx.com

Financial Performance

In 2023, Ultragenyx Pharmaceutical's revenue was $434.25 million, an increase of 19.52% compared to the previous year's $363.33 million. Losses were -$606.64 million, -14.25% less than in 2022.

Analyst Forecast

According to 15 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price forecast is $92.0, which is an increase of 122.87% from the latest price.

Price Target

$92.0

(122.87% upside)

Analyst Consensus: Strong Buy